PART 01: Executive summary • Highlights PART 02: Scope of the report • Market Overview • Top-vendor offerings PART 03: Market research methodology • Research methodology • Economic indicators PART 04: Introduction • Key market highlights PART 05: Market landscape • Market overview • Market size and forecast • Five forces analysis PART 06: Market segmentation by product • Global fecal occult testing market by FIT • Global fecal occult testing market by guaiac test • Global fecal occult testing market by stool DNA test PART 07: Market segmentation by end-user • Global fecal occult testing market by hospitals • Global fecal occult testing market by clinical diagnostic laboratories • Global fecal occult testing market by physicians' office laboratories PART 08: Geographical segmentation • Fecal occult testing market in Americas • Fecal occult testing market in EMEA • Fecal occult testing market in APAC PART 09: Market drivers • Rise in geriatric population • Government initiatives and pilot programs worldwide • Shift toward patient-centered model (POC FITs) for home use PART 10: Impact of drivers PART 11: Market challenges • High cost of FITs and limited reimbursement • Inaccuracies in diagnosis • Limited awareness and reluctance of physicians to recommend fecal occult testing PART 12: Impact of drivers and challenges PART 13: Market trends • Collaboration between research centers and manufacturers • Online marketing of fecal occult immunological test devices • Direct-to-consumer laboratory testing PART 14: Vendor landscape • Competitive scenario PART 15: Key vendor analysis • Geographical presence: Major vendors • Beckman Coulter • Eiken Chemical • Epigenomics • Quidel • Key news • Other prominent vendors PART 16: Appendix • List of abbreviations PART 17: Explore Technavio List of Exhibits Exhibit 01: Global fecal occult testing market: Three significant estimations Exhibit 02: Product offerings Exhibit 03: Colorectal cancer screening tests: Advantages and disadvantages of fecal occult testing Exhibit 04: Scale of colorectal cancer cases in UK Exhibit 05: Adoption of Cologuard in US 2014-2015 Exhibit 06: Segmentation of global fecal occult testing market Exhibit 07: Global fecal occult testing market: Impact assessment Exhibit 08: Global fecal occult testing market 2015-2020 ($ millions) Exhibit 09: New cases and deaths related to colorectal cancer per 100,000 people in US 2004-2014 Exhibit 10: Government guidelines and support in some developed countries Exhibit 11: Five forces analysis Exhibit 12: Global fecal occult testing market by product 2015 and 2020 Exhibit 13: Global fecal occult testing market by FIT: An overview Exhibit 14: Global fecal occult testing market by FIT 2015-2020 ($ millions) Exhibit 15: Comparison of FIT and guaiac test Exhibit 16: Global fecal occult testing market by guaiac test: An overview Exhibit 17: Global fecal occult testing market by guaiac test 2015-2020 ($ millions) Exhibit 18: Global fecal occult testing market by stool DNA test: An overview Exhibit 19: Global fecal occult testing market by stool DNA test 2015-2020 ($ millions) Exhibit 20: Global fecal occult testing market segmentation by end-user 2015 Exhibit 21: Revenue generated by diagnostic and medical laboratories in US 2009-2014 Exhibit 22: Global fecal occult testing market segmentation by geography 2015 and 2020 Exhibit 23: Fecal occult testing market in Americas: An overview Exhibit 24: Fecal occult testing market in Americas 2015-2020 ($ millions) Exhibit 25: Fecal occult testing market in Americas: Metrics analysis for various countries 2015 and 2020 Exhibit 26: Fecal occult testing market in US: Key takeaways Exhibit 27: Fecal occult testing market in EMEA: An overview Exhibit 28: Colorectal cancer mortality per 100,000 individuals in European countries 2003 and 2013 Exhibit 29: Fecal occult testing market in EMEA 2015-2020 ($ millions) Exhibit 30: Fecal occult testing market in EMEA: Metrics analysis of various countries 2015 and 2020 Exhibit 31: Fecal occult testing market in UK: Key takeaways Exhibit 32: Fecal occult testing market in APAC: An overview Exhibit 33: Colorectal cancer mortality per 100,000 individuals in APAC 2003 and 2013 Exhibit 34: Fecal occult testing market in APAC 2015-2020 ($ millions) Exhibit 35: Fecal occult testing market in APAC: Metrics analysis for various countries 2015 and 2020 Exhibit 36: People in age group 60 years and above worldwide 2010-2050 Exhibit 37: Government initiatives for colorectal cancer and fecal occult testing in some countries Exhibit 38: Some POC FITs available in market Exhibit 39: Impact of drivers Exhibit 40: Study results: Potential barriers affecting adoption of FOBTs Exhibit 41: Impact of drivers and challenges Exhibit 42: Some collaborations and their impact Exhibit 43: Some companies and their distribution partners Exhibit 44: Global fecal occult testing market: Competitive structure analysis 2015 Exhibit 45: Global fecal occult testing market: Competitive landscape analysis Exhibit 46: Market penetration of vendors of fecal occult testing kits 2015 Exhibit 47: Global fecal occult testing market: Strategic success factors of companies Exhibit 48: Major vendors: Regional analysis Exhibit 49: Beckman Coulter: Profile summary Exhibit 50: Beckman Coulter: Strength analysis Exhibit 51: Beckman Coulter: Growth strategy matrix Exhibit 52: Beckman Coulter: Opportunity assessment Exhibit 53: Eiken Chemical: Profile summary Exhibit 54: Eiken Chemical: Strength analysis Exhibit 55: Eiken Chemical: Growth strategy matrix Exhibit 56: Eiken Chemical: Opportunity assessment Exhibit 57: Epigenomics: Profile summary Exhibit 58: Epigenomics: Strength analysis Exhibit 59: Epigenomics: Growth strategy matrix Exhibit 60: Epigenomics: Opportunity assessment Exhibit 61: Quidel: Profile summary Exhibit 62: Quidel: Strength analysis Exhibit 63: Quidel: Growth strategy matrix Exhibit 64: Quidel: Opportunity assessment Exhibit 65: Other prominent vendors

Beckman Coulter, Eiken Chemical, Epigenomics, Quidel, Abbott Laboratories, AccuBioTech, Applied Proteomics, ASAN PHARM, Assure Tech. (Hangzhou), BIOHIT Healthcare, EDP Biotech, FUJIREBIO, GeneNews, NanoRepro AG, Nantong Egens Biotechnology, Orion Diagnostica, Polymedco, Quest Diagnostics, Randox, VolitionRx.